| SECURITIES AND EXCHANGE
COMMISSION Washington, D.C. 20549 |
SCHEDULE 13G |
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment
No. 4
)*
|
Eterna Therapeutics Inc. (Name of Issuer) |
Common Stock, par value $0.005 per share (Title of Class of Securities) |
114082209 (CUSIP Number) |
10/29/2024 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule
13d-1(b) |
 Rule
13d-1(c) |
| Rule
13d-1(d) |
SCHEDULE 13G |
| CUSIP No. | 114082209 |
| 1 | Names of Reporting Persons John D. Halpern | ||||||||
| 2 | Check the appropriate box if a member of a Group (see
instructions)
(a)
(b) | ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization UNITED STATES | ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting
Person 5,136,581.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes
certain shares (See Instructions) | ||||||||
| 11 | Percent of class represented by amount in row (9) 9.99 % | ||||||||
| 12 | Type of Reporting Person (See Instructions) IN |
Comment for Type of Reporting Person:
Share counts in Rows 6, 8, and 9 represents (i) 5,136,571 shares of common stock, par value $0.005 per share (the "Common Stock") of Eterna Therapeutics Inc., a Delaware corporation (the "Issuer") held by the John D. Halpern Revocable Trust (the "Trust"), a trust of which John D. Halpern and Katherine H. Halpern are trustees; and (ii) 10 shares of Common Stock of the Issuer (the "Warrant Shares") issuable upon exercise of that certain Pre-Funded Common Stock Purchase Warrant, in substantially the form as the form of Warrant filed as Exhibit 10.3 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 29, 2024 (the "Warrant"), issued by the Issuer in favor of the Trust which may be exercised at any time, at a nominal exercise price of $0.005 per Warrant Share.
Pursuant to the terms of the Warrant, the Reporting Person cannot exercise the Warrant for Warrant Shares to the extent the Reporting Person would beneficially own, after any such conversion or exercise, more than 9.99% of the outstanding shares of Common Stock (the "Blocker"). The table excludes 114,990 shares of Common Stock issuable upon exercise of the Warrant because of the Blocker.
Percentage of ownership in Row 11 is based on an aggregate of 51,374,723 shares of Common Stock outstanding, which is derived from: (i) 51,374,713 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024; plus (ii) the 10 Warrant Shares issuable upon exercise of the Warrant within 60 days, which are deemed outstanding pursuant to Rule 13d-3(d)(1)(i) of the Securites Exchange Act of 1934, as amended.
SCHEDULE 13G |
| CUSIP No. | 114082209 |
| 1 | Names of Reporting Persons Katherine H. Halpern | ||||||||
| 2 | Check the appropriate box if a member of a Group (see
instructions)
(a)
(b) | ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization UNITED STATES | ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting
Person 5,136,581.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes
certain shares (See Instructions) | ||||||||
| 11 | Percent of class represented by amount in row (9) 9.99 % | ||||||||
| 12 | Type of Reporting Person (See Instructions) IN |
Comment for Type of Reporting Person:
As noted above, Share counts in Rows 6, 8, and 9 represents (i) 5,136,571 shares of Common Stock of the Issuer held by the Trust, of which John D. Halpern and Katherine H. Halpern are trustees; and (ii) 10 shares of the Warrant Shares issuable upon exercise of the Warrant.
Also as noted above, the Warrant has a Blocker and the table excludes 114,990 shares of Common Stock issuable upon exercise of the Warrant because of the Blocker.
Percentage of ownership in Row 11 is based on an aggregate of 51,374,723 shares of Common Stock outstanding, which is derived from: (i) 51,374,713 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024; plus (ii) the 10 Warrant Shares issuable upon exercise of the Warrant within 60 days, which are deemed outstanding pursuant to Rule 13d-3(d)(1)(i) of the Securites Exchange Act of 1934, as amended.
SCHEDULE 13G |
| Item 1. | ||
| (a) | Name of issuer: Eterna Therapeutics Inc. | |
| (b) | Address of issuer's principal executive
offices: 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 | |
| Item 2. | ||
| (a) | Name of person filing: John D. Halpern
Katherine H. Halpern | |
| (b) | Address or principal business office or, if
none, residence: P.O. Box 540 Portsmouth, New Hampshire 03802 | |
| (c) | Citizenship: United States | |
| (d) | Title of class of securities: Common Stock, par value $0.005 per share | |
| (e) | CUSIP No.: 114082209 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o); | |
| (b) | Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | |
| (c) | Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | |
| (d) | Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | |
| (e) | An
investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | |
| (f) | An
employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); | |
| (g) | A
parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); | |
| (h) | A
savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813); | |
| (i) | A
church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | A
non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S.
institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: | |
| (k) | Group,
in accordance with Rule 240.13d-1(b)(1)(ii)(K). | |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned: See Row 9 of cover page for each Reporting Person. | |
| (b) | Percent of class: See Row 11 of cover page for each Reporting Person. % | |
| (c) | Number of shares as to which the person has: | |
| (i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person. | ||
| (ii) Shared power to vote or to direct the
vote: See Row 6 of cover page for each Reporting Person. | ||
| (iii) Sole power to dispose or to direct the
disposition of: See Row 7 of cover page for each Reporting Person. | ||
| (iv) Shared power to dispose or to direct the
disposition of: See Row 8 of cover page for each Reporting Person. | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the
best of my knowledge and belief, I certify that the information set forth in this statement is
true, complete and correct. |
|
|
|
|